JP2005528089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528089A5 JP2005528089A5 JP2003564091A JP2003564091A JP2005528089A5 JP 2005528089 A5 JP2005528089 A5 JP 2005528089A5 JP 2003564091 A JP2003564091 A JP 2003564091A JP 2003564091 A JP2003564091 A JP 2003564091A JP 2005528089 A5 JP2005528089 A5 JP 2005528089A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- prostaglandin
- receptor subtype
- expression
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150105978 EP3 gene Proteins 0.000 claims 31
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims 30
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/060,902 US20030157599A1 (en) | 2002-01-30 | 2002-01-30 | Gene for peripheral arterial occlusive disease |
| PCT/IB2003/000300 WO2003064471A2 (en) | 2002-01-30 | 2003-01-29 | Gene for peripheral arterial occlusive disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528089A JP2005528089A (ja) | 2005-09-22 |
| JP2005528089A5 true JP2005528089A5 (https=) | 2006-03-16 |
Family
ID=27658354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564091A Pending JP2005528089A (ja) | 2002-01-30 | 2003-01-29 | 末梢動脈閉塞疾患の遺伝子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030157599A1 (https=) |
| EP (1) | EP1476553A2 (https=) |
| JP (1) | JP2005528089A (https=) |
| AU (1) | AU2003201728B2 (https=) |
| CA (1) | CA2474759A1 (https=) |
| WO (1) | WO2003064471A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074842A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3) |
| WO2004074830A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 iii (prostaglandin e2 ep3 iii) |
| WO2004075813A2 (en) * | 2003-02-26 | 2004-09-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 ii (prostaglandin e2 ep3 ii) |
| WO2004075814A2 (en) * | 2003-02-26 | 2004-09-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 i (prostaglandin e2 ep3 i) |
| US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| US20100074896A1 (en) * | 2006-11-30 | 2010-03-25 | The Johns Hopkins University | Antagonists of pge2 ep3 receptors |
| WO2008148463A1 (en) * | 2007-06-02 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Splice-variants of g-protein coupled receptor ep3 and uses thereof |
| MX2010003371A (es) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3508865B2 (ja) * | 1992-02-24 | 2004-03-22 | 周 成宮 | プロスタグランジンｅ受容蛋白質、それをコードするｄｎａおよびその製造法 |
| WO1995000552A1 (en) * | 1993-06-25 | 1995-01-05 | Merck Frosst Canada Inc. | Prostaglandin receptor ep3 and dna encoding it |
| US6057433A (en) * | 1993-11-19 | 2000-05-02 | Allergan Sales, Inc. | Nucleic acid encoding human EP3 prostaglandin receptor |
-
2002
- 2002-01-30 US US10/060,902 patent/US20030157599A1/en active Pending
-
2003
- 2003-01-29 EP EP03700429A patent/EP1476553A2/en not_active Withdrawn
- 2003-01-29 CA CA002474759A patent/CA2474759A1/en not_active Abandoned
- 2003-01-29 WO PCT/IB2003/000300 patent/WO2003064471A2/en not_active Ceased
- 2003-01-29 JP JP2003564091A patent/JP2005528089A/ja active Pending
- 2003-01-29 AU AU2003201728A patent/AU2003201728B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase | |
| Zou et al. | Reduction of mNAT1/hNAT2 contributes to cerebral endothelial necroptosis and Aβ accumulation in Alzheimer’s disease | |
| Apostolatos et al. | Insulin promotes neuronal survival via the alternatively spliced protein kinase CδII isoform | |
| Mokres et al. | Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice | |
| US20130316337A1 (en) | Methods of Diagnosing and Treating an Inflammatory Response | |
| Bolognin et al. | An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide | |
| US12109265B2 (en) | Drug regimen for treatment of cerebral ischemia | |
| JP2008517928A5 (https=) | ||
| US10160973B2 (en) | Nucleic acid aptamers binding to vascular endothelial growth factor receptors | |
| Zhao et al. | PGF2α facilitates pathological retinal angiogenesis by modulating endothelial FOS‐driven ELR+ CXC chemokine expression | |
| BR112014016493A2 (pt) | sinalização slit-robo para diagnóstico e tratamendo de doença renal | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| JP2005528089A5 (https=) | ||
| CN107405405B (zh) | 治疗和/或预防慢性阻塞性肺病的新组合物和方法 | |
| JP2010507666A5 (https=) | ||
| Lee et al. | nArgBP2-SAPAP-SHANK, the core postsynaptic triad associated with psychiatric disorders | |
| JP2009513118A5 (https=) | ||
| JP2022530651A (ja) | アルファ－シヌクレインアッセイ | |
| JP2008502355A5 (https=) | ||
| US11642395B2 (en) | Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH) | |
| US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
| EP2795337B1 (en) | Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions | |
| CN102741277A (zh) | 在治疗运动神经元疾病中的IFNγ抑制剂 | |
| US20210038575A1 (en) | Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis | |
| TW200831898A (en) | Treatment of insulin resistance |